Inpharma 1473 - 5 Feb 2005

■ Topical civamide 0.075% cream* improves painand physical function in patients with osteoarthritis ofthe knee, according to results from a phase III study.This multicentre study involved 695 patients withmoderate-to-severe osteoarthritis pain that was notadequately controlled** after receiving stable doses oforal COX-2 inhibitors or NSAIDs for ≥ 1 month.Patients received civamide 0.075% cream or a controlcream containing civamide 0.01%, in addition to theirexisting medication, for 12 weeks. Significantimprovements in pain and physical function, accordingto WOMAC subscale scores, were observed amongcivamide recipients, compared with the control group.Furthermore, increased patient satisfaction wasreported among those receiving civamide, comparedwith patients receiving the control cream.* Winston Laboratories; phase III for musculoskeletal pain in theUS** Western Ontario McMaster Osteoarthritis Index (WOMAC)pain score of > 9

Winston Laboratories Inc. Topical Civamide Cream 0.075% EffectivelyReduces Osteoarthritis Pain Without Harmful, Systemic Side Effects. MediaRelease : 25 Jan 2005. Available from: URL: http://www.winstonlabs.com 809044415

1

Inpharma 5 Feb 2005 No. 14731173-8324/10/1473-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved